The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group

  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
    1. About this group
    2. Reviews
      1. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaReview
      2. Aerobic physical exercise for adult patients with haematological malignanciesReview
      3. Alemtuzumab for patients with chronic lymphocytic leukaemiaReview
      4. Alkylating agents for Waldenstrom's macroglobulinaemiaReview
      5. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remissionReview
      6. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphomaReview
      7. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantationReviewNew
      8. Anthracycline-containing regimens for treatment of follicular lymphoma in adultsReview
      9. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disordersReview
      10. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemiaReview
      11. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaReview
      12. Bisphosphonates in multiple myeloma: a network meta-analysisReview
      13. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donorsReview
      14. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsReview
      15. Bortezomib for the treatment of multiple myelomaReview
      16. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphomaReview
      17. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaReview
      18. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer riskReview
      19. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaReview
      20. Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemiaReview
      21. Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersReview
      22. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphomaReview
      23. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationReview
      24. Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopeniaReview
      25. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantationReview
      26. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantationReview
      27. Deferasirox for managing iron overload in people with myelodysplastic syndromeReview
      28. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationReview
      29. Early versus deferred treatment for early stage multiple myelomaReview
      30. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaReview
      31. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaReview
      32. Erythropoietin or darbepoetin for patients with cancerReview
      33. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataReview
      34. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemiaReview
      35. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesReview
      36. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromesReview
      37. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaReview
      38. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaReview
      39. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsReview
      40. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adultsReview
      41. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantationReview
      42. Interferon-alpha for maintenance of follicular lymphomaReview
      43. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionReview
      44. Interventions for early stage Hodgkin's disease in childrenReviewWithdrawn
      45. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantationReview
      46. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisReview
      47. Meditation for adults with haematological malignanciesReview
      48. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantationReview
      49. Pathogen-reduced platelets for the prevention of bleedingReview
      50. Plasma transfusions prior to insertion of central lines for people with abnormal coagulationReviewNew
      51. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsReview
      52. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphomaReview
      53. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapyReview
      54. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantationReview
      55. Purine Antagonists for Chronic Lymphocytic LeukaemiaReview
      56. Rituximab as maintenance therapy for patients with follicular lymphomaReview
      57. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaReview
      58. The role of additional radiotherapy for primary central nervous system lymphomaReview
      59. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)Review
      60. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agentsReview
      61. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionReview
      62. Therapeutic interventions for Burkitt lymphoma in childrenReview
      63. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationReview
      64. TPO receptor agonist for chronic idiopathic thrombocytopenic purpuraReview
      65. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemiaReview
      66. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopeniaReview
      67. Vaccines for prophylaxis of viral infections in patients with hematological malignanciesReview
      68. Yoga in addition to standard care for patients with haematological malignanciesReview
    3. Protocols
      1. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic reviewProtocol
      2. Antibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProtocolWithdrawn
      3. Arsenic trioxide for the treatment of acute promyelocytic leukaemiaProtocol
      4. Chemotherapy versus surgery with or without adjuvant chemotherapy and radiotherapy for localised primary gastric diffuse large B-cell lymphomaProtocolWithdrawn
      5. Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphomaProtocol
      6. Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disordersProtocolNew
      7. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))Protocol
      8. The effects of allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed multiple myelomaProtocolWithdrawn
      9. Erythropoiesis-stimulating agents for myelodysplastic syndromesProtocolWithdrawn
      10. Granulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsProtocolWithdrawn
      11. High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient dataProtocol
      12. Hypomethylating agents for adult patients with acute myeloid leukaemiaProtocolWithdrawn
      13. Hypomethylating agents for patients with myelodysplastic syndromeProtocolWithdrawn
      14. Idiotype vaccination for Non-Hodgkin lymphomaProtocolWithdrawn
      15. Imatinib for treating patients with chronic myelogeneous leukemiaProtocolWithdrawn
      16. Interventions for preventing hemorrhagic cystitis in patients undergoing hematopoietic stem cell transplantationProtocolWithdrawn
      17. Interventions for treatment of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantationProtocol
      18. Intravenous immunoglobulins for the treatment of infections in patients with haematological cancersProtocolWithdrawn
      19. Low dose cytarabine monotherapy for acute myeloid leukaemiaProtocolWithdrawn
      20. Low dose cytarabine monotherapy for myelodysplastic syndromesProtocol
      21. Maintenance therapies for multiple myelomaProtocol
      22. Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunityProtocol
      23. Non-pharmacological measures for preventing opportunistic infection in patients with haematological malignanciesProtocol
      24. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survivalProtocol
      25. Pegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for patients after hematopoietic stem cell transplantationProtocol
      26. Pegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for peripheral stem cell mobilizationProtocolWithdrawn
      27. Pegylated liposomal doxorubicin for multiple myelomaProtocol
      28. Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysisProtocol
      29. Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemiaProtocolWithdrawn
      30. Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemiaProtocol
      31. Radiotherapy for advanced-stage aggressive non-Hodgkin lymphomaProtocol
      32. Restrictive versus liberal red blood cell transfusion strategies for patients with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell supportProtocol
      33. The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationProtocolWithdrawn
      34. Role of rituximab for first-line or relapsed aggressive B-cell lymphomaProtocol
      35. Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantationProtocolWithdrawn
      36. Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myelomaProtocol
      37. Thrombopoietin mimetics for patients with myelodysplastic syndromesProtocol
      38. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumoursProtocol
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group